Sarah Cannon Research Institute clinical trials

Also known as SCRI.

Part of McKesson Corporation, which holds 51% as of 2022-10-31. Source

The registry lists 29 studies whose lead sponsor is Sarah Cannon Research Institute or one of 1 company grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 29 of 29.

• MYLUNG Consortium Part 3: Observational StudyRecruitingNCT05885698

  Sponsor listed in the registry: US Oncology Research · First submitted after US Oncology Research became part of Sarah Cannon Research Institute

• MYLUNG Consortium Study Protocol 2Active, not recruitingNCT05644808

  Sponsor listed in the registry: US Oncology Research · First submitted after US Oncology Research became part of Sarah Cannon Research Institute

• PhII ICb With/Without Erbitux in MBC PtsActive, not recruitingNCT00248287Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Study of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04782687Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast CancerActive, not recruitingNCT03379428Phase 1/2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast CancerCompletedNCT02187991Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• TAC Versus TC for Adjuvant Breast CancerCompletedNCT00493870Phase 3

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast CancerTerminatedNCT02229149Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by EverolimusCompletedNCT02229136Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• STAR Cape+BKM120 MBC With Brain MetCompletedNCT02000882Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOXTerminatedNCT02425683Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal CancerCompletedNCT00252564Phase 3

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Vidaza to Restore Hormone Thx ProstateCompletedNCT00384839Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Phase II Sunitinib Prog Met AIPCCompletedNCT00599313Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Synera Venipuncture PainCompletedNCT01744197Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Sunitinib Non Small Cell Lung Cancer Patients Over 70CompletedNCT00864721Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)CompletedNCT00661492Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Ixabepilone + Carboplatin Metastatic Breast CancerCompletedNCT01075100Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Docetaxel+Oxali+/-Cetux Met Gastric/GEJCompletedNCT00517829Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia PatientsCompletedNCT00254163Phase 3

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Adj TC + Herceptin Early Stage Breast CancerCompletedNCT00493649Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Ph2 Gem/Nov/Rituxan Rel/Ref MantleCellCompletedNCT00656084Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Doxil & Carboplatin Plus HER2+ in Metastatic Breast CancerCompletedNCT00303108Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Pre-op Rectal ChemoRad +/- CetuximabCompletedNCT00527111Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Gemzar, Cisp, Sunitinib Urothelial CaCompletedNCT00821327Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic CancerStatus unknownNCT01934634Phase 1

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)CompletedNCT01909362

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Triple Negative Breast Cancer Biomarker StudyCompletedNCT01111175

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute

• Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's LymphomaTerminatedNCT00250861Phase 2

  Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute